Xi Mai

Synthesis, Anticancer Evaluation and Docking Study of 3- Benzyloxyhydantoin Derivatives.

A series of 3-benzyloxyhydantoin derivatives were designed and synthesized by introducing hydroxyurea pharmacophore into hydantoin rigid scaffold. The cytotoxic activities of the target compounds were evaluated in vitro against three cancer cell lines. Compounds 5b, 5c, 5e, 5g, 6c and 6g displayed high activity on all of the three cancer cell lines and the most promising compounds were 5g, 6g with IC50 values of 0.04 and 0.01µM. Binding of derivatives for the ribonucleotide reductase (RR) was investigated by use of molecular docking studies. Our findings show that modification at the C5 position of hydantoin with isopropyl or isobutyl was favorable to increasing binding affinity to the active site of the RR receptor and antiproliferative activity.

1-(3-Chloro­benz­yloxy)urea

The asymmetric unit of the crystal structure of the title compound, C8H9ClN2O2, contains four independent molecules. The dihedral angles between the urea N—(C=O)—N planes and the benzene rings are 83.3 (3), 87.8 (1), 89.1 (1) and 17.5 (2)° in the four molecules. Extensive N—H⋯O hydrogen bonding is present in the crystal structure.

1-(2-Fluoro-benz-yl)-1-(2-fluoro-benz-yl-oxy)urea.

In the title hydroxyurea derivative, C15H14F2N2O2, the dihedral angle between the two benzene rings is 48.64 (19)°. The urea group forms dihedral angles of 48.1 (2) and 79.2 (2)° with the two benzene rings. In the crystal, inversion dimers linked by pairs of N—H⋯O hydrogen bonds occur, and further N—H⋯O links lead to chains of molecules.